ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $79.00 Average Price Target from Brokerages

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has been assigned an average rating of “Buy” from the nine research firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $79.75.

Several equities analysts have recently issued reports on the stock. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price objective for the company. Jefferies Financial Group began coverage on shares of ANI Pharmaceuticals in a research report on Friday. They set a “buy” rating and a $80.00 price objective for the company. JPMorgan Chase & Co. began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an “overweight” rating and a $85.00 price objective for the company. Finally, StockNews.com upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday.

Insider Activity

In other news, CFO Stephen P. Carey sold 7,500 shares of ANI Pharmaceuticals stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total transaction of $418,425.00. Following the completion of the transaction, the chief financial officer now directly owns 154,468 shares in the company, valued at $8,617,769.72. This trade represents a 4.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00. Following the transaction, the vice president now owns 80,545 shares of the company’s stock, valued at $5,100,914.85. This represents a 0.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 10,700 shares of company stock worth $610,201 over the last three months. 12.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. US Bancorp DE lifted its position in shares of ANI Pharmaceuticals by 842.9% during the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock valued at $33,000 after purchasing an additional 531 shares in the last quarter. KBC Group NV lifted its position in shares of ANI Pharmaceuticals by 89.2% during the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock valued at $70,000 after purchasing an additional 600 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of ANI Pharmaceuticals during the fourth quarter valued at about $166,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of ANI Pharmaceuticals by 24.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after purchasing an additional 579 shares in the last quarter. Finally, Rafferty Asset Management LLC bought a new position in shares of ANI Pharmaceuticals during the fourth quarter valued at about $200,000. 76.05% of the stock is owned by institutional investors.

ANI Pharmaceuticals Price Performance

ANIP stock opened at $62.49 on Wednesday. The company has a fifty day moving average price of $58.40 and a 200-day moving average price of $58.06. The company has a market capitalization of $1.36 billion, a P/E ratio of -113.62 and a beta of 0.62. ANI Pharmaceuticals has a 52-week low of $52.50 and a 52-week high of $70.81. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.